Devicare, SL
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Devicare, SL - overview
Established
2012
Location
Barcelona, -, Spain
Primary Industry
Medical Devices & Equipment
About
Devicare, SL is a healthcare company focused on developing innovative solutions for kidney health and urinary tract conditions. Their products are designed to improve patient outcomes through effective management of related health issues. Founded in 2012 and headquartered in Barcelona, Spain, Devicare, SL specializes in health solutions for kidney and urinary tract health. The company has secured a total of 7 deals, most recently raising USD 3.
000 mn in Series A funding on January 7, 2021, led by Advanced MedTech Holdings, with participation from EMESA SL, Equity4Good, and the European Investment Fund. The founder, Rosendo Garganta, has a history in health-focused entrepreneurial ventures. Devicare's core offerings include the Lit-Control® line of dietary supplements that manage kidney stone formation and facilitate post-surgical recovery, alongside urinary hygiene products like Urogelus® and Nodorin®. The company also provides online consultations with healthcare professionals for personalized guidance, reaching customers in Italy, Spain, and Türkiye.
In the most recent year, Devicare reported a revenue of USD 2,730,892. 40 and an EBITDA of USD 341,096. 70. Their revenue model is based on direct-to-consumer sales and online consultations, with key product prices including Lit-Control® pH Balance at EUR 37.
40 and Urogelus® at EUR 16. 94. Devicare aims to enhance its product portfolio with new offerings aimed at further improving kidney health management, although specific release dates have yet to be announced. The company is exploring expansion into new markets, targeting regions with a high prevalence of urinary tract conditions.
The recent Series A funding of USD 3. 000 mn will be utilized to support these product developments and market expansions.
Current Investors
EMESA SL, Empresa Nacional de Innovacion, Ministry of Industry, Energy and Tourism
Primary Industry
Medical Devices & Equipment
Sub Industries
Biopharmaceuticals, Diagnostic Equipment
Website
www.devicare.com
Verticals
HealthTech, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Devicare, SL - timeline of key events
Devicare, SL - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 215,856.9 | 354,993.3 | 263,280 | 576,571.9 | 748,777.3 | 1,014,077.1 | 15,129,710.8 | - | - | - |
| % Revenue Growth (YoY) | - | 64.5% | (25.8%) | 119.0% | 29.9% | 35.4% | 1392.0% | - | - | - |
| EBITDA (USD) | (141,406.5) | (583,206.4) | (1,215,263.4) | (1,003,265.6) | (840,989.2) | (177,792.3) | 2,412,761.7 | - | - | - |
| Operating Income (USD) | (222,680.6) | (688,132.9) | (1,335,074.8) | (1,143,566.8) | (989,771.5) | (305,285.9) | 2,010,227.3 | - | - | - |
| Operating Margin | (103.2%) | (193.8%) | (507.1%) | (198.3%) | (132.2%) | (30.1%) | 13.3% | - | - | - |
| % EBITDA Margin | (65.5%) | (164.3%) | (461.6%) | (174.0%) | (112.3%) | (17.5%) | 15.9% | - | - | - |
| NET Income (USD) | (77,852.8) | (661,809.5) | (1,400,462.6) | (1,297,952.1) | (1,135,282.9) | (428,966) | 1,544,399.6 | - | - | - |
| % Net Margin | (36.1%) | (186.4%) | (531.9%) | (225.1%) | (151.6%) | (42.3%) | 10.2% | - | - | - |
Devicare, SL - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.